File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Radiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm

TitleRadiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm
Authors
Issue Date2015
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/WileyCDA/WileyTitle/productCd-HPB.html
Citation
HPB, 2015, v. 17 n. 3, p. 226-231 How to Cite?
AbstractOBJECTIVES: This retrospective review was conducted to compare the efficacy of radiofrequency ablation (RFA) with that of transarterial chemoembolization (TACE) in treating large (5-8 cm) unresectable solitary hepatocellular carcinomas (HCCs). METHODS: Patients with large unresectable solitary HCCs primarily treated by RFA or TACE were reviewed. The primary endpoint was overall survival. Secondary endpoints were tumour response, time to disease progression, and treatment-related morbidity and mortality. RESULTS: There were 15 patients in the RFA group. Of these, 12 achieved complete ablation, one had ablation site recurrence, and five developed complications. Median disease-free survival in this group was 13.0 months (range: 2.8-38.0 months). The TACE group included 26 patients, of whom four obtained a partial response, none achieved a complete response, and five developed complications. The median time to disease progression in this group was 8.0 months (range: 1.0-68.0 months). There were no hospital deaths in this series. Median survival was 39.8 months in the RFA group and 19.8 months in the TACE group (P = 0.257). Rates of 1-, 2- and 5-year survival were 93.3%, 86.2% and 20.9%, respectively, in the RFA group and 73.1%, 40.6% and 18.3%, respectively, in the TACE group. CONCLUSIONS: Both RFA and TACE are feasible treatments for large unresectable solitary HCCs. Both modes show comparable rates of complications and longterm survival, but RFA achieves better initial tumour control and results in better short-term survival. © 2014 International Hepato-Pancreato-Biliary Association.
DescriptionThis study was presented at the 11th World Congress of the IHPBA, 22–27 March 2014, Seoul as 'Outcomes of unresectable solitary hepatocellular carcinomas China sized 5 to 8cm treated by radiofrequency ablation versus transarterial chemoembolization' by WC Dai.
Persistent Identifierhttp://hdl.handle.net/10722/207317
ISSN
2015 Impact Factor: 2.918
2015 SCImago Journal Rankings: 1.586
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorDai, WC-
dc.contributor.authorCheung, TT-
dc.contributor.authorChok, KSH-
dc.contributor.authorChan, ACY-
dc.contributor.authorSharr, WW-
dc.contributor.authorTsang, SHY-
dc.contributor.authorYuen, WK-
dc.contributor.authorChan, SC-
dc.contributor.authorFan, ST-
dc.contributor.authorLo, CM-
dc.contributor.authorPoon, RTP-
dc.date.accessioned2014-12-19T10:20:51Z-
dc.date.available2014-12-19T10:20:51Z-
dc.date.issued2015-
dc.identifier.citationHPB, 2015, v. 17 n. 3, p. 226-231-
dc.identifier.issn1365-182X-
dc.identifier.urihttp://hdl.handle.net/10722/207317-
dc.descriptionThis study was presented at the 11th World Congress of the IHPBA, 22–27 March 2014, Seoul as 'Outcomes of unresectable solitary hepatocellular carcinomas China sized 5 to 8cm treated by radiofrequency ablation versus transarterial chemoembolization' by WC Dai.-
dc.description.abstractOBJECTIVES: This retrospective review was conducted to compare the efficacy of radiofrequency ablation (RFA) with that of transarterial chemoembolization (TACE) in treating large (5-8 cm) unresectable solitary hepatocellular carcinomas (HCCs). METHODS: Patients with large unresectable solitary HCCs primarily treated by RFA or TACE were reviewed. The primary endpoint was overall survival. Secondary endpoints were tumour response, time to disease progression, and treatment-related morbidity and mortality. RESULTS: There were 15 patients in the RFA group. Of these, 12 achieved complete ablation, one had ablation site recurrence, and five developed complications. Median disease-free survival in this group was 13.0 months (range: 2.8-38.0 months). The TACE group included 26 patients, of whom four obtained a partial response, none achieved a complete response, and five developed complications. The median time to disease progression in this group was 8.0 months (range: 1.0-68.0 months). There were no hospital deaths in this series. Median survival was 39.8 months in the RFA group and 19.8 months in the TACE group (P = 0.257). Rates of 1-, 2- and 5-year survival were 93.3%, 86.2% and 20.9%, respectively, in the RFA group and 73.1%, 40.6% and 18.3%, respectively, in the TACE group. CONCLUSIONS: Both RFA and TACE are feasible treatments for large unresectable solitary HCCs. Both modes show comparable rates of complications and longterm survival, but RFA achieves better initial tumour control and results in better short-term survival. © 2014 International Hepato-Pancreato-Biliary Association.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://www.wiley.com/WileyCDA/WileyTitle/productCd-HPB.html-
dc.relation.ispartofHPB-
dc.titleRadiofrequency ablation versus transarterial chemoembolization for unresectable solitary hepatocellular carcinomas sized 5-8 cm-
dc.typeArticle-
dc.identifier.emailDai, WC: daiwc@hku.hk-
dc.identifier.emailCheung, TT: cheung68@hku.hk-
dc.identifier.emailChok, KSH: chok6275@hku.hk-
dc.identifier.emailChan, ACY: acchan@hku.hk-
dc.identifier.emailSharr, WW: wwsharr@hku.hk-
dc.identifier.emailYuen, WK: drwkyuen@hku.hk-
dc.identifier.emailChan, SC: chanlsc@hkucc.hku.hk-
dc.identifier.emailFan, ST: stfan@hku.hk-
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hk-
dc.identifier.emailPoon, RTP: poontp@hku.hk-
dc.identifier.authorityChan, ACY=rp00310en_US
dc.identifier.authorityChan, SC=rp01568en_US
dc.identifier.authorityFan, ST=rp00355en_US
dc.identifier.authorityLo, CM=rp00412en_US
dc.identifier.authorityPoon, RTP=rp00446en_US
dc.identifier.doi10.1111/hpb.12324-
dc.identifier.pmid25284590-
dc.identifier.pmcidPMC4333783-
dc.identifier.scopuseid_2-s2.0-84922677993-
dc.identifier.hkuros241972-
dc.identifier.volume17-
dc.identifier.issue3-
dc.identifier.spage226-
dc.identifier.epage231-
dc.identifier.isiWOS:000349697600006-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats